Trial Profile
Bi-weekly capecitabine and oxaliplatin plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms PHOENiX
- 20 Sep 2018 Status changed from active, no longer recruiting to completed.
- 01 Jul 2016 Results (n=53) published in the Anticancer Research
- 01 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.